WhitTier Trust Company’s ADMA Biologics ADMA Stock Holding History

WhitTier Trust Company’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,414	Closed	-$13.1K	–	1428
2026 Q1	$13.1K	Hold	1,414	–	–	﹤0.01%	1003
2025 Q4	$25.9K	Sell	1,414 -22	-2%	-$371	﹤0.01%	846
2025 Q3	$21.1K	Buy	1,436 +400	+39%	+$6.86K	﹤0.01%	884
2025 Q2	$18.9K	Buy	+1,036	New	+$21.1K	﹤0.01%	1012

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

WhitTier Trust Company's ADMA Position: Q2 2026 in Review

WhitTier Trust Company sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 1,414 shares — an estimated $13.1K sold.

WhitTier Trust Company first reported a position in ADMA in Q2 2025 and held it in 4 quarters. The position peaked at $25.9K in Q4 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

WhitTier Trust Company reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
WhitTier Trust Company sold 1,414 ADMA Biologics shares in Q2 2026, an estimated $13.1K.
WhitTier Trust Company first reported a position in ADMA Biologics in Q2 2025 and held it in 4 quarters.
WhitTier Trust Company's ADMA Biologics position peaked at $25.9K in Q4 2025.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on WhitTier Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.